journal
MENU ▼
Read by QxMD icon Read
search

Endocrine-related Cancer

journal
https://www.readbyqxmd.com/read/28213567/vitamin-d-receptor-as-a-target-for-breast-cancer-therapy
#1
Alyson Murray, Stephen Madden, Naoise C Synnott, Rut Klinger, Darran O'Connor, Norma O'Donovan, William Gallagher, John Crown, Michael Duffy
Considerable epidemiological evidence suggests that high levels of circulating vitamin D (VD) are associated with a decreased incidence and increased survival from cancer, i.e., VD may possess anti-cancer properties. The aim of this investigation was therefore to investigate the anti-cancer potential of a low calcemic vitamin D analogue, i.e., inecalcitol and compare it with the active form of vitamin D, i.e., calcitriol, in a panel of breast cancer cell lines (n = 15). Using the MTT assay, IC50 concentrations for response to calcitriol varied from 0...
February 17, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28209634/cognitive-decline-in-prostate-cancer-patients-undergoing-adt
#2
Niamh Liana Mundell, Robin M Daly, Helen Macpherson, Steve F Fraser
Androgen deprivation therapy (ADT) is an effective and widely prescribed treatment for prostate cancer (PCa), but it is associated with multiple treatment induced adverse effects that impact on various musculoskeletal and cardiometabolic health outcomes. Emerging research has shown that ADT is also associated with cognitive impairment, which has been linked to a loss of independence, increased falls and fracture risk and greater use of medical services. The aim of this review is to outline the evidence related to the effect of ADT use on cognitive function, and propose a role for exercise training as part of usual care to prevent and/or manage cognitive impairments for PCa survivors on ADT...
February 16, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28193698/the-innate-and-adaptive-infiltrating-immune-systems-as-targets-for-breast-cancer-immunotherapy
#3
Andrew Mk Law, Elgene Lim, Christopher Ormandy, David Gallego-Ortega
A cancer cell-centric view has long dominated the field of cancer biology. Research efforts have focussed on aberrant cancer cell signalling pathways and on changes to cancer cell DNA. Mounting evidence demonstrates that many cancer-associated cell types within the tumour stroma co-evolve and support tumour growth and development, greatly modifying cancer cell behaviour, facilitating invasion and metastasis, and controlling dormancy and sensitivity to drug therapy. Thus, these stromal cells represent potential targets for cancer therapy...
February 13, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28159857/glycosylation-is-a-global-target-for-androgen-control-in-prostate-cancer-cells
#4
Jennifer Munkley
Changes in glycan composition are common in cancer and can play important roles in all of the recognised hallmarks of cancer. We recently identified glycosylation as a global target for androgen control in prostate cancer cells and further defined a set of 8 glycosylation enzymes (GALNT7, ST6GalNAc1, GCNT1, UAP1, PGM3, CSGALNACT1, ST6GAL1 and EDEM3), which are also significantly up-regulated in prostate cancer tissue. These 8 enzymes are under direct control of the androgen receptor (AR) and are linked to the synthesis of important cancer-associated glycans such as sialyl-Tn (sTn), sialyl LewisX (SLeX), O-GlcNAc and chondroitin sulphate...
February 3, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28148541/silencing-the-roadblocks-to-effective-tnbc-treatments-by-sirna-nanoparticles
#5
Jenny G Parvani, Mark W Jackson
Over the past decade, RNA interference (RNAi) has been ubiquitously utilized to study biological function in vitro, however limitations were associated with its utility in vivo. More recently, small interfering RNA (siRNA) nanoparticles with improved biocompatibility have gained prevalence as a potential therapeutic option for the treatment of various diseases. The adaptability of siRNA nanoparticles enables the delivery of virtually any siRNA, which is especially advantageous for therapeutic applications in heterogeneous diseases that lack unifying molecular features, such as triple negative breast cancer (TNBC)...
February 1, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28143811/lipomatous-tumours-in-adrenal-gland-who-updates-and-clinical-implications
#6
Alfred Lam
Adrenal lipomatous tumour is a group of adrenal tumours with a significant component of adipose tissue. According to the current World Health Organization (WHO) classification of tumours of endocrine organs, adrenal myelolipoma is the only entity amongst the group of tumours being described. In the literature, other more recently documented adrenal lipomatous tumours included 24 lipomas, 32 teratomas and 16 angiomyolipomas. Rare fatty tumours of the adrenal gland comprised liposarcoma, hibernoma, adrenocortical tumours with fat component and rare adrenal tumours with fat component...
January 31, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28137980/nelfinavir-inhibits-proliferation-and-induces-dna-damage-in-thyroid-cancer-cells
#7
Kirk Jensen, Athanasios D Bikas, Aneeta Patel, Yevgeniya Kushchayeva, John Costello, Dennis McDaniel, Kenneth Burman, Vasily Vasko
The HIV protease inhibitor Nelfinavir (NFV) inhibits PI3K/AKT and MAPK/ERK signaling pathways, emerging targets in thyroid cancers. We examined the effects of NFV on cancer cells that derived from follicular (FTC), papillary (PTC) and anaplastic (ATC) thyroid cancers. NFV (1-20 μM) was tested in FTC133, BCPAP and SW1736 cell lines. The effects of NFV on cell proliferation were determined in vitro using real-time microscopy and by flow cytometry. DNA damage, apoptotic cell death, and expression of molecular markers of epithelial-mesenchymal transition (EMT) were determined by Western blot and real-time PCR...
January 30, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28122798/pituitary-acromegaly-not-one-disease
#8
Sylvia L Asa, Walter Kucharczyk, Shereen Ezzat
Acromegaly has traditionally been regarded as a monomorphous disorder resulting from a benign pituitary adenoma. Increasing evidence, however, is highlighting that this disorder is associated with a spectrum of morphologically distinct pituitary tumors with variable clinical, biochemical and radiologic features and differing therapeutic outcomes that are attributed to different genetic and epigenetic changes. These data underscore the need for developing a more refined clinicopathological risk stratification system and implementing personalized targeted therapeutic approaches...
January 25, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28115389/hypo-methylation-mediates-chromosomal-instability-in-pancreatic-net
#9
Ilaria Marinoni, Astrid Wiederkehr, Tabea Wiedmer, Sophia Pantasis, Annunziata Di Domenico, Rasmus Frank, Erik Vassella, Anja Maria Schmitt, Aurel Perren
DAXX and or ATRX loss occur in 40% of pancreatic neuro-endocrine tumors (PanNETs). PanNETs negative for DAXX or ATRX show an increased risk of relapse. The tumor-associated pathways activated upon DAXX or ATRX loss and how this event may induce chromosomal instability (CIN) and alternative lengthening telomeres (ALT) are still unknown. Both DAXX and ATRX are involved in DNA methylation regulation. DNA methylation of heterochromatin and of non-coding sequences is extremely important for the maintenance of genomic stability...
January 23, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28104681/copy-number-variations-of-e2f1-a-new-genetic-risk-factor-for-testicular-cancer
#10
Maria Santa Rocca, Andrea Di Nisio, Arianna Marchiori, Marco Ghezzi, Giuseppe Opocher, Carlo Foresta, Alberto Ferlin
Testicular germ cell tumor (TGCT) is one of the most heritable forms of cancer. In last years many evidence suggested that constitutional genetic factors, mainly single nucleotide polymorphisms, can increase its risk. However, the possible contribution of copy-number variations (CNVs) in TGCT susceptibility has not been substantially addressed. Indeed, an increasing number of studies have focused on the effect of CNVs on gene expression and on the role of these structural genetic variations as risk factors for different forms of cancer...
January 19, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28104680/evaluation-of-thyroseq-v2-performance-in-thyroid-nodules-with-indeterminate-cytology
#11
Pablo Valderrabano, Laila Khazai, Marino E Leon, Zachary J Thompson, Zhenjun Ma, Christine H Chung, Julie E Hallanger-Johnson, Kristen J Otto, Kara D Rogers, Barbara Centeno, Bryan McIver
ThyroSeq v2 claims high positive (PPV) and negative (NPV) predictive values in a wide range of pre-test risks of malignancy in indeterminate thyroid nodules (ITNs) (categories B-III and B-IV of the Bethesda system). We evaluated ThyroSeq v2 performance in a cohort of patients with ITNs seen at our Academic Cancer Center from September 2014 to April 2016, in light of the new diagnostic criteria for non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Our study included 182 patients (76% female) with 190 ITNs consecutively tested with ThyroSeq v2...
January 19, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28062546/the-clinical-importance-of-quantifying-fat-distribution-during-androgen-deprivation
#12
Stephen John Foulkes, Robin M Daly, Steve Fraser
Androgen deprivation therapy (ADT) is now considered a mainstay in the treatment of metastatic and locally advanced prostate cancer (PCa). Despite well-established benefits of ADT in relation to overall survival, this treatment has been associated with a number of adverse effects, particularly with regard to key cardiometabolic risk factors including the development of insulin resistance, dyslipidaemia and increases in total and regional fat mass. In non-ADT populations, increased levels of visceral adipose tissue (VAT) are thought to be a key mediator of the increased cardiometabolic risk associated with weight gain, but this has received limited attention in men treated with ADT...
January 6, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28049633/progressive-epigenetic-dysregulation-in-neuroendocrine-tumour-liver-metastasis
#13
Anna Karpathakis, Harpreet Dibra, Christodoulos Pipinikas, Andrew Feber, Tiffany Morris, Joshua M Francis, Dahmane Oukrif, Dalvinder Mandair, Marinos Pericleous, Mullan Mohmaduvesh, Stefano Serra, Olagunju Ogunbiyi, Marco Novelli, Tu Vinh Luong, Sylvia L Asa, Matthew H Kulke, Christos Toumpanakis, Tim Meyer, Martyn Caplin, Stephan Beck, Christina Thirlwell
Dear Editor The incidence of small intestinal neuroendocrine tumours (SINETs) is increasing and distant metastases are present at diagnosis in 70% of cases, the liver being the most common site of metastasis. Despite this, our understanding of the mechanisms underlying metastatic progression of SINETs is currently limited and prior studies of the molecular biology of SINET liver metastases (LM) have been performed predominantly in small cohorts utilising candidate based techniques.
January 3, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27965278/regression-of-advanced-neuroendocrine-tumors-among-patients-receiving-placebo
#14
Vito Amoroso, Giorgio Maria Agazzi, Elisa Roca, Nicola Fazio, Alessandra Mosca, Marco Ravanelli, Francesca Spada, Roberto Maroldi, Alfredo Berruti
Neuroendocrine tumors have a heterogeneous clinical behavior, many of them having an indolent disease course and some of them depicting an aggressive pattern. Neuroendocrine tumors may even undergo spontaneous remission, but this phenomenon has never been quantified and characterized. In this study, we performed a literature-based meta-analysis of all prospective randomized trials in which an active experimental treatment was compared with a placebo control arm. Our analysis clearly showed that a subset of NET patients (approximately 6% of those randomized to placebo) achieved tumor shrinkage greater than 10% from baseline, and this proportion was similar across the examined studies...
December 13, 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27895137/successful-response-to-pegylated-interferon-alpha-in-a-recurrent-paraganglioma
#15
Thibault Bahougne, Alessio Imperiale, Gerlinde Averous, Gerard Chabrier, Nelly Burnichon, Anne-Paule Gimenez-Roqueplo, Nassim Dali-Youcef, Rossella Libé, Eric Baudin, Catherine Roy, Herve Lang, Laurence Kessler
INTRODUCTION: Early and accurate identification of recurrences in patients with aggressive paraganglioma (PGL) poses significant challenges. Moreover, the most appropriate therapeutic strategy for recurrent PGL remains to be established. RESULTS: We report the case of 52-year-old man with a history of recurrent, sporadic, left retroperitoneal PGL that relapsed twice (at eight and nine years after the first surgical intervention). At the time of the second recurrence, 2-deoxy-2-[fluorine-18]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) demonstrated a pathologically increased tracer uptake in multiple nodular lesions (10-15 mm in size) located close to the remnant of the left renal pedicle and in the left lombar paravertebral region...
November 28, 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28062545/a-review-of-estrogen-receptor-androgen-receptor-genomics-in-male-breast-cancer
#16
REVIEW
Tesa M Severson, Wilbert Zwart
Male breast cancer is a rare disease, of which little is known. In contrast to female breast cancer, the very vast majority of all cases are positive for estrogen receptor alpha (ERα), implicating the function of this steroid hormone receptor in tumor development and progression. Consequently, adjuvant treatment of male breast cancer revolves around inhibition of ERα. In addition, the androgen receptor (AR) gradually receives more attention as a relevant novel target in breast cancer treatment. Importantly, the rationale of treatment decision making is strongly based on parallels with female breast cancer...
March 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28093480/comprehensive-screening-for-pd-l1-expression-in-thyroid-cancer
#17
Soomin Ahn, Tae Hyuk Kim, Sun Wook Kim, Chang Seok Ki, Hye Won Jang, Jee Soo Kim, Jung Han Kim, Jun-Ho Choe, Jung Hee Shin, Soo Yeon Hahn, Young Lyun Oh, Jae Hoon Chung
PD-L1 expression is being considered a potential biomarker for response of anti-PD-1 or anti-PD-L1 agents in various tumors. The reported frequency of PD-L1 positivity varies in thyroid carcinomas, and multiple factors may contribute to the variability in PD-L1 positivity. We evaluated the PD-L1 expression in various thyroid cancers on a large scale. A total of 407 primary thyroid cancers with a median 13.7-year of follow-up were included. We evaluated the frequency of PD-L1 expression using a rabbit monoclonal antibody (clone SP142)...
February 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28062544/somatic-mutation-profiling-of-hobnail-variant-of-papillary-thyroid-carcinoma
#18
Luca Morandi, Alberto Righi, Francesca Maletta, Paola Rucci, Fabio Pagni, Marco Gallo, Sabrina Rossi, Leonardo Caporali, Anna Sapino, Ricardo V Lloyd, Sofia Asioli
Hobnail variant of papillary thyroid carcinoma (HPTC) represents a recently described, aggressive and rare group of thyroid tumors with poorly understood pathogenesis. Molecular data about this group of cancers are few, and a more detailed molecular characterization of these tumors is needed. The main objective of the study is to define a comprehensive molecular typing of HPTC. Eighteen patients affected by HPTC, including eighteen primary tumors and four lymph node metastases, were screened for NRAS, KRAS, HRAS, BRAF, TP53, PIK3CA, hTERT, PTEN, CDKN2A, EGFR, AKT1, CTNNB1 and NOTCH1 gene mutations...
February 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28049632/paleogenetic-study-of-ancient-dna-suggestive-of-x-linked-acrogigantism
#19
LETTER
Albert Beckers, Daniel Fernandes, Frederic Fina, Mario Novak, Angelo Abati, Liliya Rostomyan, Albert Thiry, L'Housine Ouafik, Bertrand Pasture, Ron Pinhasi, Adrian F Daly
No abstract text is available yet for this article.
February 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27998958/bisphenol-a-and-its-analogues-disrupt-centrosome-cycle-and-microtubule-dynamics-in-prostate-cancer
#20
Shuk-Mei Ho, Rahul Rao, Sarah To, Emma Schoch, Pheruza Tarapore
Humans are increasingly exposed to structural analogues of bisphenol A (BPA), as BPA is being replaced by these compounds in BPA-free consumer products. We have previously shown that chronic and developmental exposure to BPA is associated with increased prostate cancer (PCa) risk in human and animal models. Here, we examine whether exposure of PCa cells (LNCaP, C4-2) to low-dose BPA and its structural analogues (BPS, BPF, BPAF, TBBPA, DMBPA and TMBPA) affects centrosome amplification (CA), a hallmark of cancer initiation and progression...
February 2017: Endocrine-related Cancer
journal
journal
32030
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"